Next-gen RNAi drugmaker City prices $200M IPO

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver. 

By Delilah Alvarado • Oct. 16, 2026

Biogen-backed Estuary nabs $93M for kidney disease gene therapy

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."

By Jacob Bell • Oct. 16, 2026

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.

By BioPharma Dive staff

Belgian startup revives Galapagos CAR-T research

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.

By Jonathan Gardner • Oct. 15, 2026

Iambic, an AI drug discovery specialist, banks $150M in an IPO

Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”

By Gwendolyn Wu • Oct. 14, 2026

Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.

By Jonathan Gardner • Oct. 14, 2026

J&J earnings set ‘negative tone’; Shkreli vs. the FTC

A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.

By Ben Fidler • Oct. 14, 2026

Another Paragon spinout goes public through reverse merger

One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform the reputation for reverse mergers — quickly executing on a complicated deal.

By Jacob Bell • Oct. 13, 2026

BioNTech mRNA cancer immunotherapy misses first objective in key study

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.

By Delilah Alvarado • Oct. 13, 2026

Roche extends China deal streak with $1B pact for RNAi obesity drug

An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.

By Jonathan Gardner • Oct. 13, 2026

First Tracks climbs on ‘impressive’ celiac study data

Initial study findings strengthened some analysts’ belief that First Tracks’ drug, one of a few in development aimed at the protein CD122, might have “pipeline-in-a-product” potential. 

By Delilah Alvarado • Oct. 12, 2026

Parkinson’s cell therapy developer files to go public

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.

By Jacob Bell • Oct. 12, 2026

Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

By Ben Fidler • Oct. 12, 2026

FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.

By BioPharma Dive staff • Oct. 9, 2026

This week in charts: What’s driving biotech’s recent pullback?

The latest installment in BioPharma Dive’s data visualization series features a look at the factors pressuring biotech stocks of late and the frenetic pace of startup buyouts this year. 

By Gwendolyn Wu • Oct. 9, 2026

TRex Bio prices $117M IPO to support immune drug work

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

By Gwendolyn Wu • Oct. 9, 2026

Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture cash.

By BioPharma Dive staff • Oct. 7, 2026

A Takeda spinout builds case for its Parkinson’s drug

Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has Phase 3 data in hand.

By Jacob Bell • Oct. 7, 2026

Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds

The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind its counterparts in the U.S. and China.

By Gwendolyn Wu • Oct. 6, 2026

ArriVent collapses on disappointing lung cancer data

More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share. 

By Delilah Alvarado • Oct. 6, 2026

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

By Jonathan Gardner • Oct. 6, 2026

The top biopharma conferences in 2027

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.

By Ben Fidler • Oct. 6, 2026

Optogenetics researchers win a Nobel Prize; Roche bets on Alector brain drug

The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and CSL cut licensing deals and the FDA endorsed broader use of a Lilly medicine.

By Ben Fidler • Oct. 5, 2026

This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking

The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.

By Jonathan Gardner • Oct. 2, 2026

Lilly, Foghorn part ways; Wave’s FDA-approved plans

The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.

By Gwendolyn Wu • Oct. 1, 2026

Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame. 

By Jonathan Gardner • Sept. 30, 2026